12400 High Bluff Drive
121 articles with Evofem Biosciences
- Advancing Precommercial Activities in Preparation for Phexxi™ Commercial Launch in September 2020 - - Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea on Track for Q4 2020 Initiation - - Management to Host Conference Call Tuesday, August 4, 2020 at 11:00 a.m. EDT - [04-August-2020] SAN DIEGO , Aug. 4, 2020 /PRNewswire/ --
Evofem Biosciences' CEO Saundra Pelletier Named to PharmaVOICE100 - The Most Inspiring People in Life Sciences
Evofem Biosciences, Inc. (NASDAQ: EVFM) is proud to announce that CEO Saundra Pelletier was named to the PharmaVOICE 100 Most Inspiring People, an annual list of the 100 most innovative, influential and inspirational people in the life-sciences industry.
Evofem Biosciences to Report Second Quarter 2020 Results and Provide Corporate Update on Tuesday, August 4, 2020
Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the second quarter ended June 30, 2020 .
Evofem Biosciences Announces Peer-Reviewed Publication of the Pivotal Phase 3 AMPOWER Study Results For Phexxi™ (lactic acid, citric acid and potassium bitartrate) in Contraception
Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, today announced that Contraception , an international, peer-reviewed, reproductive health journal, published the primary efficacy and safety results from the Phase 3 AMPOWER study evaluating Phexxi™ (lactic acid, citric acid and potassium bitartrate) f
- On-Track for September Launch of Phexxi™, the First FDA-Approved, Non-Hormonal, On-Demand Prescription Contraceptive Gel - - Advancing EVO100 for the Prevention of Urogenital Chlamydia and Gonorrhea - - ~ $136 Million Gross Proceeds Raised; Funding Expected to Carry the Company into Q2 2021 -
Evofem Announces Pricing of Approximately $100 Million Public Offering of Common Stock - June 03, 2020
Evofem Biosciences, Inc., a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced the pricing of an underwritten public offering of 28,500,000 shares of its common stock at a price to the public of $3.50 per share.
Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering
Heading into the first week after Memorial Day, which in the U.S. marks the typical beginning of summer, the U.S. Food and Drug Administration has a number of drug approvals on the calendar. Here’s a look.
U.S. FDA Approves Evofem Biosciences' Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy
- A New Class of Female-Controlled Birth Control for Use In-The-Moment - - Robust Telemedicine Program Will Support Access for Women - - Company to Host Conference Call on Tuesday, May 26, 2020 at 8:30 a.m. ET -
PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the final distribution ratio for the previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. (
Evofem Biosciences to Participate in Virtual Fireside Chat at RBC Capital Markets Global Healthcare Conference
Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that it will participate in the upcoming 2020 RBC Capital Markets Global Healthcare Conference.
Evofem Biosciences, Inc.today reported financial results for the three month period ended March 31, 2020.
PDL BioPharma, Inc. announces that the Company's Board of Directors has approved a distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. via a special one-time dividend to PDL stockholders.
Evofem Biosciences Announces New Location and COVID-19 Preventative Measures for 2020 Annual Meeting Scheduled for May 12, 2020
Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that the location of its annual general meeting scheduled for May 12, 2020 at 8:00 am PDT has been moved to the 6th floor boardroom at 12400 High Bluff Dr., San Diego, CA 92130.
Evofem Biosciences to Report First Quarter 2020 Results and Provide Corporate Update on Wednesday, May 6, 2020
-- Conference Call Scheduled for 11:00 a.m. ET -- -- Key U.S. Regulatory Milestones Remain on Track, Including May 25, 2020
Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that it has entered into a private Securities Purchase Agreement with a U.S.-based, healthcare-focused institutional investor
Evofem Biosciences Announces Three New Phexxi™ Data Sets Accepted for Presentation at the 2020 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
- Perfect Use Efficacy Up to 93.3%; Exploratory Findings Demonstrate Increased Sexual Satisfaction and Vaginal Lubrication; Company Provides Updated Safety Outcomes - - Abstracts Published Online Today in Obstetrics & Gynecology (The Green Journal) - [24-April-2020] SAN DIEGO , April 24, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a cli
Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that on April 9, 2020, the Compensation Committee of the Company's Board of Directors approved the grant to 20 new employees of (i) non-qualified stock option awards to purchase an aggregate of 357,000 shares of common stock, and (ii) 20,000 restricted shares of common stock awards in aggregate.
Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, announced today that Chief Executive Officer Saundra Pelletier will present an overview of the Company and business updates at the upcoming Solebury Trout Virtual Investor Conference.
Evofem Biosciences, Inc. announced that its Board of Directors has adopted a shareholder rights agreement, effective March 24, 2020, under which its stockholders will receive a dividend in the form of preferred stock purchase rights.